CureVac N.V. (CVAC) stock surged +0.98%, trading at $4.14 on NASDAQ, up from the previous close of $4.10. The stock opened at $4.13, fluctuating between $4.02 and $4.26 in the recent session.
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Employees | 999 |
Beta | 2.61 |
Sales or Revenue | $52.66M |
5Y Sales Change% | 2.333% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
CureVac N.V. (NASDAQ: CVAC) stock price is $4.14 in the last trading session. During the trading session, CVAC stock reached the peak price of $4.26 while $4.02 was the lowest point it dropped to. The percentage change in CVAC stock occurred in the recent session was 0.98% while the dollar amount for the price change in CVAC stock was $0.04.
The NASDAQ listed CVAC is part of Biotechnology industry that operates in the broader Healthcare sector. CureVac N.V. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Alexander Zehnder
Chief Executive Officer
Mr. Marco Rau L.L.M., Ph.D.
Gen. Counsel
Mr. Thorsten Schuller
Head of Corporation Communications
Slavica Stevanovic-Heck
Head of HR
Dr. Igor Splawski M.Sc., Ph.D.
Chief Scientific Officer & Member of Management Board
Dr. Ulrike Gnad-Vogt M.D., Ph.D.
Senior Vice President & Area Head of Oncology
Dr. Alexander Zehnder M.B.A., M.D.
Chief Executive Officer, MD & Member of Management Board
Dr. Sarah Fakih
Vice President Corporation Communications & Investor Relations
Dr. Alexander Zehnder
Chief Executive Officer & MD
Dr. Myriam Mendila M.D.
Chief Devel. Officer & Member of the Management Board
Dr. Franz-Werner Haas L.L.M., LL.M., LLD, Ph.D.
Managing Director
Dr. Alexander Zehnder L.L.M., Ph.D.
Chief Executive Officer, MD & Member of Management Board
Mr. Pierre Kemula B.Sc.
MD, Chief Financial Officer & Member of Management Board
Dr. Antony Blanc Ph.D.
MD, Chief Bus. Officer, Chief Commercial Officer & Member of Management Board
Mr. Malte Greune Ph.D.
Chief Operating Officer, Member of Management Board & MD
CVAC's closing price is 86.91% higher than its 52-week low of $2.22 where as its distance from 52-week high of $5.28 is -21.59%.
Number of CVAC employees currently stands at 999.
Official Website of CVAC is: https://www.curevac.com
CVAC could be contacted at phone 497 071 98830 and can also be accessed through its website. CVAC operates from Friedrich-Miescher-Strasse 15, Tübingen, 72076, Germany.
CVAC stock volume for the day was 823.44K shares. The average number of CVAC shares traded daily for last 3 months was 766.63K.
The market value of CVAC currently stands at $928.63M with its latest stock price at $4.14 and 224.31M of its shares outstanding.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com